Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even und...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abraham Tettey, Yujie Jiang, Xiaohui Li, Ying Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	nitric oxide pulmonary arterial hypertension phosphodiesterase 5 inhibitor proliferation crosstalk Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/626691f9f4364a179d1a83e96c743654
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:626691f9f4364a179d1a83e96c743654
record_format	dspace
spelling	oai:doaj.org-article:626691f9f4364a179d1a83e96c7436542021-11-12T09:04:43ZTherapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway1663-981210.3389/fphar.2021.767002https://doaj.org/article/626691f9f4364a179d1a83e96c7436542021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.767002/fullhttps://doaj.org/toc/1663-9812Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.Abraham TetteyYujie JiangXiaohui LiXiaohui LiYing LiYing LiFrontiers Media S.A.articlenitric oxidepulmonary arterial hypertensionphosphodiesterase 5 inhibitorproliferationcrosstalkTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nitric oxide pulmonary arterial hypertension phosphodiesterase 5 inhibitor proliferation crosstalk Therapeutics. Pharmacology RM1-950
spellingShingle	nitric oxide pulmonary arterial hypertension phosphodiesterase 5 inhibitor proliferation crosstalk Therapeutics. Pharmacology RM1-950 Abraham Tettey Yujie Jiang Xiaohui Li Xiaohui Li Ying Li Ying Li Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
description	Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.
format	article
author	Abraham Tettey Yujie Jiang Xiaohui Li Xiaohui Li Ying Li Ying Li
author_facet	Abraham Tettey Yujie Jiang Xiaohui Li Xiaohui Li Ying Li Ying Li
author_sort	Abraham Tettey
title	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
title_short	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
title_full	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
title_fullStr	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
title_full_unstemmed	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
title_sort	therapy for pulmonary arterial hypertension: glance on nitric oxide pathway
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/626691f9f4364a179d1a83e96c743654
work_keys_str_mv	AT abrahamtettey therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway AT yujiejiang therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway AT xiaohuili therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway AT xiaohuili therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway AT yingli therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway AT yingli therapyforpulmonaryarterialhypertensionglanceonnitricoxidepathway
_version_	1718431051859099648

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

Ejemplares similares